PD-L1 expression, as an important biomarker for immune checkpoint inhibitors and an efficient and crucial checkpoint of acquired immune resistance in NSCLC, was found to be different among tumor specimens of different sites in patients with NSCLC [29,30,31], highlighting the magnitude of intra-tumoral immune heterogeneity. This evidence concerns the gene CD274 and neoplasm.